New diabetes drug enters Head-to-Head test against leading treatment
Disease control
Not yet recruiting
This study aims to see if a new injectable drug, PG-102, can help control blood sugar and body weight in people with type 2 diabetes. It will compare PG-102 against a placebo (inactive shot) and an approved drug, semaglutide, over 24 weeks. The goal is to gather evidence on how w…
Phase: PHASE2 • Sponsor: ProGen. Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC